Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Tocilizumab Autoinjector vs Pre-Filled Syringe in Healthy Volunteers
NCT02678988Phase 1Completed
- Sponsor
- Roche
- Start
- Feb 2016
- Primary completion
- Jun 2016
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tocilizumab in rheumatoid arthritis (RA) (6 arms), sponsored by Roche. Primary endpoints: Maximum observed serum concentration and Area under the serum concentration-time curve from time zero to last quantifiable concentration. Started Feb 2016; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02678988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02678988.